Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Connexin-Based Channel Activity Is Not Specifically Altered by Hepatocarcinogenic Chemicals

Full text
Author(s):
Leroy, Kaat [1] ; Pieters, Alanah [1] ; Cooreman, Axelle [1] ; Van Campenhout, Raf [1] ; Cogliati, Bruno [2] ; Vinken, Mathieu [1]
Total Authors: 6
Affiliation:
[1] Vrije Univ Brussel, Dept Pharmaceut & Pharmacol Sci, Ent Vitro Toxicol & Dermatocosmetol, Laarbeeklaan 103, B-1090 Brussels - Belgium
[2] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, Av Prof Dr Orlando Marques de Paiva 87, BR-05508270 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 22, n. 21 NOV 2021.
Web of Science Citations: 0
Abstract

Connexin-based channels play key roles in cellular communication and can be affected by deleterious chemicals. In this study, the effects of various genotoxic carcinogenic compounds, non-genotoxic carcinogenic compounds and non-carcinogenic compounds on the expression and functionality of connexin-based channels, both gap junctions and connexin hemichannels, were investigated in human hepatoma HepaRG cell cultures. Expression of connexin26, connexin32, and connexin43 was evaluated by means of real-time reverse transcription quantitative polymerase chain reaction analysis, immunoblot analysis and in situ immunostaining. Gap junction functionality was assessed via a scrape loading/dye transfer assay. Opening of connexin hemichannels was monitored by measuring extracellular release of adenosine triphosphate. It was found that both genotoxic and non-genotoxic carcinogenic compounds negatively affect connexin32 expression. However, no specific effects related to chemical type were observed at gap junction or connexin hemichannel functionality level. (AU)

FAPESP's process: 18/10953-9 - Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer?
Grantee:Bruno Cogliati
Support Opportunities: Regular Research Grants